Study study type PathologyT1T0Patientssample sizesROB Results

mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population

versus Standard of Care (SoC)
durvalumab plus tremelimumab
EAGLE (DT vs ICC), 2019
  NCT02369874
RCTmHNSCC - L2 - all populationdurvalumab plus tremelimumabinvestigator’s choice: cetuximab, taxane, methotrexate, or fluoropyrimidine-based regimenpatients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).of the oral cavity, oropharynx, hypopharynx, or larynx not amenable to curative therapy who had progression or recurrence during or after only one systemic treatment regimen containing a platinum agent247 / 249some concern
inconclusive
  • inconclusive 4 % increase in deaths (OS) (PE)

mHNSCC - L2 - PDL1 negative metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 negative

versus durvalumab alone
durvalumab plus tremelimumab
CONDOR (DT vs D ; PDL1 TC<25%), 2019
  NCT02319044
RCTmHNSCC - L2 - PDL1 negativedurvalumab plus tremelimumabdurvalumab monotherapypatients with recurrent or metastatic HNSCC (PD-L1-low/negative) that had progressed after 1 platinum-containing regimen in the R/M setting133 / 67high
inconclusive
  • inconclusive 17 % decrease in objective responses (ORR) (PE)
  • statistically significant 8.4-fold increase in STRAE (any grade)
versus tremelimumab
durvalumab plus tremelimumab
CONDOR (DT vs T ; PDL1 TC<25%), 2019
  NCT02319044
RCTmHNSCC - L2 - PDL1 negativedurvalumab plus tremelimumabtremelimumab monotherapypatients with recurrent or metastatic HNSCC (PD-L1-low/negative) that had progressed after 1 platinum-containing regimen in the R/M setting133 / 67high
suggested
  • inconclusive 4.2-fold increase in objective responses (ORR) (PE)